17(ss)-hydroxysteroid dehydrogenase type 1 is a predictive factor in premenopausal hormone receptor positive breast cancer treated with tamoxifen

被引：0
|
作者：
Kallstrom, A-C
Salme, R.
Ryden, L.
Gunnarsson, C.
Nordenskjold, B.
Stal, O.
机构：
[1] Helsingborg Hosp, Helsingborg, Sweden
[2] Univ Hosp, Linkoping, Sweden
[3] Univ Lund Hosp, S-22185 Lund, Sweden
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S84 / S85
页数：2
相关论文
共 50 条
  • [21] 17-BETA-HYDROXYSTEROID DEHYDROGENASE AS A MARKER OF BREAST-CANCER HORMONE DEPENDENCE
    FOURNIER, S
    ALLALI, F
    DURAND, JC
    STERKERS, N
    DEBERTRAND, P
    DIEBOLD, N
    MARTIN, PM
    KUTTENN, F
    MAUVAISJARVIS, P
    SEMAINE DES HOPITAUX, 1986, 62 (20): : 1412 - 1417
  • [22] 17-BETA-HYDROXYSTEROID DEHYDROGENASE AS A MARKER OF BREAST-CANCER HORMONE DEPENDENCE
    FOURNIER, S
    ALLALI, F
    DURAND, JC
    STERKERS, N
    DEBERTRAND, P
    DIEBOLD, N
    MARTIN, PM
    KUTTENN, F
    MAUVAISJARVIS, P
    PATHOLOGIE BIOLOGIE, 1985, 33 (06): : 659 - 664
  • [23] PROGESTERONE BINDING CYST PROTEIN IN HORMONE-RECEPTOR POSITIVE BREAST-CANCER - A PREDICTIVE FACTOR FOR EFFECT OF ADJUVANT TAMOXIFEN TREATMENT
    SOREIDE, JA
    KOLNES, J
    SKARSTEIN, A
    AAS, T
    KVINNSLAND, S
    ANTICANCER RESEARCH, 1994, 14 (5B) : 2105 - 2108
  • [24] Understanding Resistance to Tamoxifen in Hormone Receptor-Positive Breast Cancer
    Higgins, Michaela J.
    Stearns, Vered
    CLINICAL CHEMISTRY, 2009, 55 (08) : 1453 - 1455
  • [25] Recurrence prediction model using microRNA expression in hormone receptor positive and tamoxifen treated breast cancer
    Kim, Aeree
    Kim, Chungyeul
    CANCER RESEARCH, 2015, 75
  • [26] Targeting phosphoglycerate dehydrogenase (PHGDH) in combination with tamoxifen reduces hormone receptor positive breast cancer growth in vivo
    Clem, Brian F.
    Imbert-Fernandez, Yoannis
    Petri, Belinda
    Klinge, Carolyn
    CANCER RESEARCH, 2023, 83 (07)
  • [27] 17β-hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark.
    Collin, Lindsay Jane
    Kjaersgaard, Anders
    Ahern, Thomas P.
    Goodman, Michael
    McCullough, Lauren E.
    Waller, Lance A.
    Christensen, Kristina B.
    Damkier, Per
    Hamilton-Dutoit, Stephen J.
    Lauridsen, Kristina
    Chistiansen, Peer M.
    Ejlertsen, Bent
    Sorensen, Henrik Toft
    Cronin-Fenton, Deirdre
    Lash, Timothy L.
    CANCER RESEARCH, 2021, 81 (13)
  • [28] Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients
    Kirkegaard, Tove
    McGlynn, Liane M.
    Campbell, Fiona M.
    Mueller, Sven
    Tovey, Sian M.
    Dunne, Barbara
    Nielsen, Kirsten V.
    Cooke, Timothy G.
    Bartlett, John M. S.
    CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1405 - 1411
  • [29] 17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer
    Jansson, Agneta K.
    Gunnarsson, Cecilia
    Cohen, Maja
    Sivik, Tove
    Stal, Olle
    CANCER RESEARCH, 2006, 66 (23) : 11471 - 11477
  • [30] New insights into the substrate inhibition of human 17ss-hydroxysteroid dehydrogenase type 1
    Li, Tang
    Song, Xiaohui
    Stephen, Preyesh
    Yin, Heng
    Lin, Sheng-Xiang
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2023, 228
12345